Results 91 to 100 of about 9,592 (241)
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2015 The aim of review. To analyze antiviral activity of a new NS5A replication complex inhibitor daclatasvir in patients with chronic HCV-infection in relation to different genotypes, including patients with failure of previous antiviral therapy, with liver ...
M. V. Mayevskaya +2 more
doaj
Медицинский вестник Юга России, 2017 Objective: to give assessment of the effi cacy and safety of using asunaprevir in combination with daclatasvir in patients with chronic hepatitis C (HCV) with severe fi brosis and cirrhosis.
Elena B. Romanova +5 more
doaj +1 more source
Drugs in Context, 2020 Background: The once-daily oral combination of daclatasvir (DCV) and sofosbuvir (SOF), with or without ribavirin (RBV), is effective and well tolerated in patients with hepatitis C virus (HCV).
Rodolfo Sacco +26 more
doaj +1 more source
A hepatitis C-vírus-fertőzés és kezelésének költségvonzata [PDF]
, 2015 Absztrakt A hepatitis C-vírus-fertőzés a Föld lakosságának 2–3%-át érinti és a betegséghez társuló egyéni következmények mellett igen jelentős össztársadalmi gazdasági problémát jelent.
Hunyady, Béla, Makara, Mihály
core +1 more source
Journal of Cellular and Molecular Medicine, Volume 29, Issue 15, August 2025.ABSTRACT Colorectal cancer (CRC) ranks among the primary causes of cancer deaths worldwide. Cholesterol metabolism, tightly regulated through biosynthesis, uptake, efflux and conversion, plays a crucial role in CRC development and progression. Dysregulated cholesterol metabolism in cancer cells alters the tumour microenvironment (TME), promoting tumour
Chunyu Zhang +4 more
wiley +1 more source
Reassessment of genotype 1 hepatitis c virus subtype misclassification by LiPA 2.0: implications for direct-acting antiviral treatment [PDF]
, 2014 The accuracy of LiPA 2.0 for hepatitis C virus 1 (HCV-1) subtype classification was analyzed. LiPA 2.0 genotype results from 101 HCV-1-infected patients were compared to genotype findings determined by direct core sequencing.
Di Lello, Federico Alejandro +9 more
core +1 more source
Liver International, Volume 45, Issue 8, August 2025.ABSTRACT Background and Aims In 2024, < 10% of hepatitis C virus (HCV) cases were treated in Eastern Europe and Central Asia (EECA) and the burden remains high. We aimed to estimate the cost‐effectiveness of treating anyone with HCV (‘treat all’) or targeting people who inject drugs (PWID) in 14 middle‐income EECA countries.
Josephine G. Walker +3 more
wiley +1 more source
PLoS Pathogens, 2014 Widely used chemical genetic screens have greatly facilitated the identification of many antiviral agents. However, the regions of interaction and inhibitory mechanisms of many therapeutic candidates have yet to be elucidated.
Hangfei Qi +17 more
doaj +1 more source
Recent advances in managing chronic HCV infection: Focus on therapy in patients with severe liver disease [PDF]
, 2016 Chronic hepatitis C virus (HCV) infection still represents a major public health problem, as it is thought to be responsible for more than 350,000 deaths around the globe on a yearly basis.
Maan, R. (Raoel) +1 more
core +5 more sources
Design Principles of Nanosensors for Multiplex Detection of Contaminants in Food
Small, Volume 21, Issue 26, July 3, 2025.This review discusses recent advancements in nanoparticle‐based nanosensors for multiplex detection of food contaminants, focusing on toxins and pathogens. It highlights the design principles, sensitivity, and selectivity of these sensors, offering insights into their practical applications for food safety monitoring and inspiring future innovations ...
Yang Zhang +10 more
wiley +1 more source